Burfiralimab

N/A

Report date: 2024/02/05 17:56:51

Base Information

Drug NameBurfiralimab
Drug Alias NamehzVSF-v13hzVSF_var13HzVSF-13hzVSF
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionVimentin inhibitors
TargetsVimentin
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Arthritis, RheumatoidHepatitis B, Chronic
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryNetherlandsRussian FederationItaly +[6] 
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesImmunemed Inc
China Registration ClassN/A

Develop Information

Active CompaniesImmunemed Inc
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Arthritis, RheumatoidHepatitis B, Chronic
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A